Please fill out the Questionnaire

References:

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations

• This article provides an overview of the efficacy and safety of semaglutide for chronic weight management. Read the article on PMC - NCBI

Once-Weekly Semaglutide in Adults with Overweight or Obesity

• Published in the New England Journal of Medicine, this study examines the effects of once-weekly subcutaneous semaglutide on adults with overweight or obesity.  Read the study on NEJM

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

• This trial, featured in Nature Medicine, assesses the efficacy and safety of once-weekly subcutaneous semaglutide over a two-year period.  Read the study on Nature Medicine

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

• The Lancet presents the OASIS 1 trial, which shows the effects of daily oral semaglutide on adults with overweight or obesity.  Read the study on The Lancet

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity

• This cohort study, published by JAMA Network, suggests that semaglutide is clinically effective for weight loss at 3 and 6 months for people with overweight or obesity.  Read the study on JAMA Network